Aeterna Zentaris, a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, has selected Charleston, S.C., for its North American business and global commercial operations. Over the next five years, Aeterna Zentaris will hire staff to support commercial operations, business development, regulatory and quality assurance, manufacturing management, clinical and product development, as well as various administrative functions. The Coordinating Council for Economic Development of South Carolina has approved job development credits to Aeterna Zentaris.

David Dodd, president and CEO at Aeterna Zentaris, said, "Establishing our North American business and global commercial activities here is part of our strategic plan not only for the launch of MACRILEN in the U.S., as potentially the first FDA-approved oral product for use in evaluating growth hormone deficiency in adults, but also for our future commercial opportunities. Furthermore, this marks an important milestone in Aeterna Zentaris' transition from an R&D company into a commercially operating company.”